![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 13.50 | 13.00 | 14.00 | 13.50 | 13.50 | 13.50 | 66,213 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.2994 | -0.45 | 20.84M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/7/2024 10:00 | Wrong board mate. | ![]() jonjoalex | |
15/7/2024 14:37 | Out on a profit today. Who said trading was a bad thing. 👍 | ![]() halland75 | |
15/7/2024 08:03 | Got in at 3.50. Lucky me! | ![]() halland75 | |
15/7/2024 07:33 | Great company this. But changing position here to GDR today. Hopefully I can get in, in the 3's. Will get back in here in the future. | ![]() halland75 | |
14/7/2024 18:36 | hxxps://youtu.be/MfR | ![]() david56920 | |
13/7/2024 15:20 | Small Cap funds based on five-year performance. The sales push The long-term healthcare economics of KidneyIntelX is making it very popular with both public and private insurance providers. Renalytix has agreed a 10-year government-wide contract with the US General Services Administration for KidneyIntelX at $950 per test. This applies to more than 140 government agencies including a deal with the US Veterans Association (VA). The VA provides healthcare services to 9m veterans each year through 1,293 healthcare facilities. KidneyIntelX is also an accepted provider in 27 Medicaid State programs. The private sector has taken a liking to the product as well. Coverage has been agreed with 20 private health insurance providers, including HealthFirst, one of New York State’s largest not-for-profit health insurance companies with more than 1.5m members. Renalytix seemingly has a great product and the agreements with the insurance companies are very promising, but the business is still at a pre-commercial stage. In the full year to 30 June 2021, it generated just $1.5m in revenue. In the same period, administrative expenses and finance expenses were $33.3m and $7.95m, respectively, which contributed to losses for the period increasing to $31.0m from $9.25m. | ![]() david56920 | |
12/7/2024 16:17 | was America closed today ? | ![]() arab3 | |
12/7/2024 09:49 | Already showing a profit. Looking forward to America joining the party later. Good luck guys and enjoy your weekend, but above all Good Luck England. 🏆 🏆 🏆 | ![]() halland75 | |
12/7/2024 09:07 | Just bought a little bit more. | ![]() halland75 | |
12/7/2024 08:21 | This move up has not finished. Volume in the US was colossal yesterday, I don't think markets realise how big a deal the RNS is of yesterday. Check Out the Novo Nordisk angle, they are the makers of Ozempic. I think the rally continues today. KidneyIntelX will be available for patients 1st August 2024. I bought today. 👍 | ![]() halland75 | |
11/7/2024 22:03 | $0.40 is circa 15-16p | ![]() thiopia | |
11/7/2024 13:25 | UK lagging US price US price RNLX at $0.60 is equivalent to around 23-24p here US price RNLX at $0.50 is equivalent to around 19-20p here | ![]() thiopia | |
11/7/2024 12:25 | this news from from Steno Copenhagen is significant | ![]() robow | |
25/6/2024 15:57 | Looks like.i didnt miss much... | ![]() ivan danko | |
17/6/2024 12:48 | The coverage determination enables Medicaid to pay for tests. FDA approval, inclusion in treatment guidelines and now billable under Medicaid, the test and analysis is fully endorsed. However not many clinicians have used the test yet……the credibility and expectation of use should drive take up. US Clinicians are averse to taking on legal risk - and so will follow the guidelines. The company probably needs to find an ambulance chasing lawyer to prosecute some cases where the test should have been used but was not. | ![]() 1jat | |
16/6/2024 17:59 | Why is last weeks news so important? | ![]() bertiebingo | |
16/6/2024 16:33 | If you think you’re too late here try verici dx. Poised for greatness in a similar sector | ![]() collywobbler | |
14/6/2024 15:22 | Ivan there still plenty of gains to be had here. | ![]() bri15 | |
14/6/2024 14:55 | Im too late to get in now..damn.. | ![]() ivan danko | |
14/6/2024 14:46 | US 20% up,that's just the start. | ![]() bri15 | |
14/6/2024 14:44 | F..k aye it is 😀 | ![]() bri15 | |
14/6/2024 14:17 | Is this a promising company..i mean 14mil kits to US at 950 dollars... | ![]() ivan danko | |
14/6/2024 14:05 | I be glued to Nasdaq on open,it's got to start high,and then keep rising, they will know the importance of today's RNS, unlike UK fools | ![]() bri15 | |
14/6/2024 14:03 | Yank market will rocket this. | ![]() bri15 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions